Huntington's disease (HD) is a late-onset, neurodegenerative disease for which there are currently no cures nor disease-modifying treatments. Here we report the identification of several potential anti-inflammatory targets for HD using an ex vivo model of HD that involves the acute transfection of human mutant huntingtinbased constructs into rat brain slices. This model recapitulates key components of the human disease, including the formation of intracellular huntingtin protein (HTT)-containing inclusions and the progressive neurodegeneration of striatal neurons-both occurring within the native tissue context of these neurons. Using this "high-throughput biology" screening platform, we conducted a hypothesis-neutral screen of a collection of drug-like compounds which identified several anti-inflammatory targets that provided neuroprotection against HTT fragment-induced neurodegeneration. The nature of these targets provide further support for non-cell autonomous mechanisms mediating significant aspects of neuropathogenesis induced by mutant HTT fragment proteins.
Introduction
HD arises from the inheritance of dominant, mutant alleles of the huntingtin gene (HD) containing expansions in the polyglutamine domain of HTT that exceed~35 glutamines (Gusella and Macdonald, 2006) . HD affects approximately 5-7 individuals per 100,000 in Western countries, with some 35,000 people suffering from HD in the United States alone (Walker, 2007) . Despite the landmark identification and cloning of the HD gene in 1993 (Huntington's Disease Collaborative Research Group, 1993) , there are still no clinically validated, disease-modifying drug targets for HD and only palliative treatments are currently available. Indeed, the normal functions of HTT remain uncertain, and while disease mechanism(s) presumably involve gains-of-function from the polyglutamine expansion, they may also involve loss of normal function of the HTT protein as well as interference with the function of the normal allele (Borrell-Pages et al., 2006; Cattaneo et al., 2005; Imarisio et al., 2008) .
The lack of clinically validated targets for this fatal disease places an urgent need on the development of biologically relevant and clinically predictive models to support the discovery and development of new targets and drug candidates. One powerful discovery path in the pharmaceutical industry is to screen large compound libraries (often containing N 1 million compounds) using in vitro assays based on an identified/hypothesized molecular target, ideally one that has previously been validated in clinical usage. This is often followed by cell-based secondary screens, and eventually by demonstration of safety and efficacy in animal models. Although numerous cell-based HD assays are available (Fecke et al., 2009; Varma et al., 2008) , and a variety of transgenic and knock-in models of HD have been developed in recent years (Menalled et al., 2009) , such an approach depends critically on the hypothetical framework of the original target selection being directly translatable into efficacy in cells, animal models, and eventually humans.
An alternative strategy to a target-based drug discovery approach is phenotypic screening using disease relevant in vitro models. While some disease processes can be recapitulated adequately in dissociated Neurobiology of Disease 43 (2011) 248-256 
